The global Parkinson’s disease drug market is anticipated to grow at a significant CAGR during the forecast period. Parkinson’s disease (PD) is a disorder of the central nervous system. It is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Additionally, levodopa controls the symptoms of the condition, particularly slow movements and stiff, rigid body parts and is the most commonly prescribed medicine for PD. The major factor for the growth of the market during the forecast period is the increasing prevalence of Parkinson’s disease across the globe.
According to the Parkinson Foundation, almost one million people are living with PD in the US which is expected to rise to 1.2 million in 2030. Additionally, approximately 60,000 Americans are diagnosed with PD each year and more than 10 million people are living with PD globally. Further, Parkinson disease increases with age, however, an estimated 4% of people with PD are diagnosed before age 50. Moreover, the prevalence of PD in men are 1.5 times as compared to women. Hence, the increasing prevalence of this disease is in turn driving the growth of the global Parkinson’s disease drug market.
Some major players in the market include AbbVie Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co. Inc., and Teva Pharmaceuticals Industries Ltd. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, Optimus Pharma declared that it has received DCGI approval for its Anti-Parkinson’s drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing “off” episodes.
To Request a Sample of our Report on Parkinson’s Disease Drug Market: https://www.omrglobal.com/request-sample/parkinsons-disease-drug-market-overview
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Mechanism of Action
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- AbbVie Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co. Inc., and Teva Pharmaceuticals Industries Ltd.
Parkinson’s Disease Drug Market Report by Segment
By Action
- Dopamine Agonists
- Anticholinergic
- MAO-B inhibitors
- Amantadine
- Carbidopa-levodopa
- COMT Inhibitors
- Others
A full Report of Parkinson’s Disease Drug Market is Available @ https://www.omrglobal.com/industry-reports/parkinsons-disease-drug-market-overview
Parkinson’s Disease Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
